Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.

Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, GrĂ¼ndemann D, Otto G, Galle PR, Schuchmann M, Zimmermann T.

BMC Cancer. 2012 Mar 22;12:109. doi: 10.1186/1471-2407-12-109.

2.

Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma.

Lautem A, Heise M, Gräsel A, Hoppe-Lotichius M, Weiler N, Foltys D, Knapstein J, Schattenberg JM, Schad A, Zimmermann A, Otto G, Lang H, Galle PR, Schuchmann M, Zimmermann T.

Int J Oncol. 2013 Apr;42(4):1297-304. doi: 10.3892/ijo.2013.1840. Epub 2013 Feb 22.

PMID:
23440379
3.

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.

Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E.

Hepatology. 2009 Oct;50(4):1227-40. doi: 10.1002/hep.23103.

PMID:
19591196
4.

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma.

Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H, Schwab M.

Genome Med. 2011 Dec 23;3(12):82. doi: 10.1186/gm298.

6.

Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.

Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ, Briz O.

Hepatology. 2013 Sep;58(3):1065-73. doi: 10.1002/hep.26425. Epub 2013 Jul 30.

PMID:
23532667
7.

Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M.

PLoS One. 2011;6(7):e22163. doi: 10.1371/journal.pone.0022163. Epub 2011 Jul 14.

8.

Downregulation of MAGI1 associates with poor prognosis of hepatocellular carcinoma.

Zhang G, Liu T, Wang Z.

J Invest Surg. 2012 Apr;25(2):93-9. doi: 10.3109/08941939.2011.606875. Epub 2011 Sep 26.

PMID:
21942217
9.

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.

Mohelnikova-Duchonova B, Brynychova V, Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Melichar B, Soucek P.

Cancer Chemother Pharmacol. 2013 Sep;72(3):669-82. doi: 10.1007/s00280-013-2246-2. Epub 2013 Aug 11.

PMID:
23934321
10.

Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma.

Namisaki T, Schaeffeler E, Fukui H, Yoshiji H, Nakajima Y, Fritz P, Schwab M, Nies AT.

Drug Metab Dispos. 2014 Dec;42(12):2033-40. doi: 10.1124/dmd.114.059832. Epub 2014 Sep 17.

PMID:
25231932
11.

Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis.

Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP.

J Transl Med. 2012 May 24;10:106. doi: 10.1186/1479-5876-10-106.

12.

Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension.

Sallinen R, Kaunisto MA, Forsblom C, Thomas M, Fagerudd J, Pettersson-Fernholm K, Groop PH, Wessman M; Finnish Diabetic Nephropathy Study Group.

Ann Med. 2010 May 6;42(4):296-304. doi: 10.3109/07853891003777109.

PMID:
20429798
13.

Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis.

Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y, Zhang Y.

Mol Cell Biochem. 2013 Jun;378(1-2):99-106. doi: 10.1007/s11010-013-1599-5. Epub 2013 Mar 11.

PMID:
23475171
14.

Overexpression of HOXA1 correlates with poor prognosis in patients with hepatocellular carcinoma.

Zha TZ, Hu BS, Yu HF, Tan YF, Zhang Y, Zhang K.

Tumour Biol. 2012 Dec;33(6):2125-34. doi: 10.1007/s13277-012-0472-6. Epub 2012 Aug 4.

PMID:
22864671
15.

Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival.

Chen SP, Zhang LS, Fu BS, Zeng XC, Yi HM, Jiang N.

Medicine (Baltimore). 2015 Jan;94(4):e423. doi: 10.1097/MD.0000000000000423.

PMID:
25634174
16.

The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma.

Liu AW, Cai J, Zhao XL, Xu AM, Fu HQ, Nian H, Zhang SH.

J Clin Pathol. 2009 Nov;62(11):1003-8. doi: 10.1136/jcp.2009.066944.

PMID:
19861558
17.

Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma.

Chen XQ, He JR, Wang HY.

Med Oncol. 2012 Sep;29(3):1843-9. doi: 10.1007/s12032-011-0075-x. Epub 2011 Oct 11.

PMID:
21987076
18.
19.

Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma.

Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M, Coggi G, Bosari S.

BMC Cancer. 2009 Apr 27;9:125. doi: 10.1186/1471-2407-9-125.

20.

[Expression of Raf kinase inhibitor protein and its significance in invasion and metastasis of hepatocellular carcinoma].

Wu XH, Wang SX, Yang YJ, Li JK, Xu Z, Tang RF.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):358-62. Chinese.

PMID:
21875465
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk